Search results for " monoclonal"

showing 10 items of 807 documents

Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine.

2008

Abstract Purpose: We recently reported that anionic phospholipids, principally phosphatidylserine, become exposed on the external surface of vascular endothelial cells in tumors, probably in response to oxidative stresses present in the tumor microenvironment. In the present study, we tested the hypothesis that a chimeric monoclonal antibody that binds phosphatidylserine could be labeled with radioactive arsenic isotopes and used for molecular imaging of solid tumors in rats. Experimental Design: Bavituximab was labeled with 74As (β+, T1/2 17.8 days) or 77As (β−, T1/2 1.6 days) using a novel procedure. The radionuclides of arsenic were selected because their long half-lives are consistent w…

MaleCancer ResearchPathologymedicine.medical_specialtyBiodistributionBavituximabmedicine.drug_classPhosphatidylserinesMonoclonal antibodyArticleArsenicchemistry.chemical_compoundIn vivomedicineTumor Cells CulturedAnimalsTissue DistributionPlatelet activationRadioisotopesTumor microenvironmentbiologyNeovascularization PathologicAntibodies MonoclonalProstatic NeoplasmsPhosphatidylserineMolecular biologyXenograft Model Antitumor AssaysRatsOncologychemistryRadioimmunodetectionPositron-Emission Tomographybiology.proteinEndothelium VascularAntibodymedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Expression of L- and M2-pyruvate kinases in proliferating oval cells and cholangiocellular lesions developing in the livers of rats fed a methyl-defi…

1994

Male outbred Sprague-Dawley rats were fed a choline-deficient diet containing 0.1% w/w DL-ethionine (CDE) for up to 22 weeks. The expression of the pyruvate kinase isoenzymes L (L-PK) and M2 (M2-PK) was immunohistochemically analyzed in liver slices from rats killed 4, 10, 14 and 22 weeks after starting the treatment. M2-PK was detected in bile duct epithelial cells of untreated rats and in proliferating oval cells, cholangiofibroses and cholangiofibromas of CDE-fed animals. Thus, M2-PK can be viewed as a positive marker of the bile duct epithelial/oval cell compartment. L-PK, a parenchymal cell-specific protein in untreated rat liver, was not present in proliferating oval cells, but was co…

MaleCancer ResearchPathologymedicine.medical_specialtyNecrosisLiver cytologyPyruvate KinaseCellBiologyCholangiocarcinomaRats Sprague-DawleyNecrosisLiver Neoplasms ExperimentalParenchymamedicineAnimalsEthionineBile ductAntibodies MonoclonalGeneral MedicineImmunohistochemistryEpitheliumCholine DeficiencyRatsBile Ducts Intrahepaticmedicine.anatomical_structureBile Duct NeoplasmsLiverHepatocytemedicine.symptomPrecancerous ConditionsCell DivisionPyruvate kinaseCarcinogenesis
researchProduct

Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer.

2013

Intra-tumor injection of immunotherapeutic agents is often the most effective, likely because of concomitant modification of tumor microenvironment. We tested an immunotherapeutic regimen consisting of CpG oligonucleotides and of adenovirus-mediated gene delivery of CCL16 chemokine directly into orthotopically implanted prostate tumors by ultrasound-guided injection, followed by systemic administration of an anti-IL-10R antibody. This combination treatment induced rapid stromal rearrangement, characterized by massive leukocyte infiltration and large areas of necrosis, a scenario that eventually led to complete tumor rejection and systemic immunity in 75 % of the treated mice. In vivo T lymp…

MaleCancer ResearchPathologymedicine.medical_specialtyStromal cellmedicine.medical_treatmentImmunologyFluorescent Antibody TechniqueGene deliveryCD8-Positive T-LymphocytesInjections Intralesionalprostate cancer;immunotherapyAdenoviridaeImmunoenzyme TechniquesProstate cancerMiceTumor Cells CulturedImmunology and AllergyMedicineAnimalsHumansCell ProliferationUltrasonographyTumor microenvironmentbusiness.industryAntibodies MonoclonalProstatic NeoplasmsImmunotherapyT lymphocyteGenetic Therapyprostate cancermedicine.diseaseCombined Modality TherapyInterleukin-10Mice Inbred C57BLOncologyOligodeoxyribonucleotidesChemokines CCSystemic administrationImmunotherapybusinessCD8Cancer immunology, immunotherapy : CII
researchProduct

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model

2008

Trastuzumab (Herceptin) has improved therapy of breast cancer. Only patients overexpressing ERBB2 are treated with trastuzumab, whereas its use in tumours without ERBB2 expression is useless. This led to the concept that the subgroup of trastuzumab-sensitive tumours is ‘ERBB2-dependent', meaning that ERBB2 signalling is indispensable for growth of these tumours. We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue. ERBB2 mRNA and protein expression were downregulated below detection limit leading to a macroscopically complete tumour remission within 14 days. Tumour remission was accompanied by a strong decrease in proliferation, a m…

MaleCancer ResearchReceptor ErbB-2AKT1AKT2ApoptosisMiceTrastuzumabPKBskin and connective tissue diseasesERBB2Mitogen-Activated Protein Kinase 3biologyERK1/2herceptinAntibodies MonoclonalCytochromes cImmunohistochemistrynude miceGene Expression Regulation NeoplasticOncologyTetracyclinesKi-67Ki-67Femalemedicine.drugmedicine.medical_specialtyBlotting WesternDown-RegulationMice NudeAntineoplastic AgentsProtein Serine-Threonine KinasesAntibodies Monoclonal Humanizedresistance3-Phosphoinositide-Dependent Protein Kinasesbreast cancerDownregulation and upregulationresponse to therapyInternal medicineHER2medicineAnimalsRNA Messengercytochrome c releaseProtein kinase Bneoplasmstumour developmentCell Proliferationhumanised monoclonal antibodyAktCancerMammary Neoplasms ExperimentalTrastuzumabmedicine.diseaseEndocrinologyKi-67 AntigenApoptosisDrug Resistance Neoplasmbiology.proteinCancer researchreceptor tyrosine kinaseTranslational TherapeuticsProto-Oncogene Proteins c-aktBritish Journal of Cancer
researchProduct

ERGO: A pilot study of ketogenic diet in recurrent glioblastoma

2014

Limiting dietary carbohydrates inhibits glioma growth in preclinical models. Therefore, the ERGO trial (NCT00575146) examined feasibility of a ketogenic diet in 20 patients with recurrent glioblastoma. Patients were put on a low-carbohydrate, ketogenic diet containing plant oils. Feasibility was the primary endpoint, secondary endpoints included the percentage of patients reaching urinary ketosis, progression-free survival (PFS) and overall survival. The effects of a ketogenic diet alone or in combination with bevacizumab was also explored in an orthotopic U87MG glioblastoma model in nude mice. Three patients (15%) discontinued the diet for poor tolerability. No serious adverse events attri…

MaleCancer ResearchStatement (logic)medicine.medical_treatmentSalvage treatmentPilot ProjectsBioinformaticsGastroenterologyMicegliomaClinical endpoint1306 Cancer ResearchglucoseArticlesMiddle AgedCombined Modality TherapyBevacizumabTreatment OutcomeTolerabilityOncologyketogenic dietFemale2730 OncologyDiet Ketogenicmedicine.drugAdultmedicine.medical_specialtyBevacizumabMice NudeAntineoplastic Agents610 Medicine & healthMistakeRecurrent GliomaBiologyAntibodies Monoclonal HumanizedInternal medicineGliomamedicineAnimalsHumansddc:610Adverse effectAgedbusiness.industryRecurrent glioblastomaGeneral surgeryKetosisNeoplasms Experimentalmedicine.diseaseSurvival Analysis10040 Clinic for NeurologySurgeryQuality of LifeNeoplasm Recurrence LocalKetosisGlioblastomabusinessmetabolismfeasibilityKetogenic dietInternational Journal of Oncology
researchProduct

Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation.

2007

Telomeres cap chromosomal ends and are shortened throughout a lifetime. Additional telomere erosion has been documented during conventional chemotherapy or hematopoietic stem cell transplantation. Previous studies of stem cell transplantation reported variable amounts of telomere shortening with inconsistent results regarding the persistence of telomere shortening. Here we have prospectively studied telomere length and proliferation kinetics of hematopoietic cells in aggressive non-Hodgkin lymphoma patients who underwent a four-course high-dose chemotherapy protocol combined with triple autologous stem cell transplantation. We observed sustained telomere shortening in hematopoietic cells af…

MaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationAntibodies Monoclonal Murine-DerivedAutologous stem-cell transplantationAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorLymphocytesProspective StudiesCellular SenescenceEtoposideMyelopoiesisLymphoma Non-HodgkinAntibodies MonoclonalHematologyMiddle AgedTelomereCombined Modality TherapyHaematopoiesisVincristineFemaleStem cellRituximabCell DivisionPrednisoloneTransplantation AutologousDrug Administration ScheduleGeneticsmedicineHumansMolecular BiologyCyclophosphamideChemotherapyPeripheral Blood Stem Cell Transplantationbusiness.industryCell BiologyMyeloablative Agonistsmedicine.diseaseHematopoietic Stem CellsTelomereLymphomaTransplantationClinical Trials Phase III as TopicDoxorubicinImmunologyCancer researchbusinessGranulocytesExperimental hematology
researchProduct

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

2015

Purpose Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome. Patients and Methods SWOG participants were previously untreated patients with FL enrolled onto SWOG clinical trials (S9800, S9911, or S0016) involving CHOP chemotherapy plus an anti-CD20 antibody (rituximab or iodine-131 tositumomab) between 1998 and 2008. Participants included in our second independent cohort were also previously untreated patients with FL enrolled onto the Lymphoma Study Association (LYSA) PRIMA trial of rituximab plus chemotherapy (randomly assigned to rituximab maintenanc…

MaleCancer Researchmedicine.medical_specialtyTime FactorsFollicular lymphomaKaplan-Meier EstimateCHOPGastroenterologyTositumomabDisease-Free SurvivalRisk FactorsTandem Mass SpectrometryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineVitamin D and neurologyHumansProspective StudiesVitamin DProspective cohort studyCyclophosphamideLymphoma FollicularProportional Hazards Modelsbusiness.industryHazard ratioAntibodies MonoclonalORIGINAL REPORTSMiddle Agedmedicine.diseaseVitamin D DeficiencySurgeryTreatment OutcomeOncologyDoxorubicinVincristineCohortDisease ProgressionPrednisoneRituximabFemalebusinessRituximabBiomarkersmedicine.drugChromatography LiquidJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.

2012

Cetuximab is a human-murine chimeric monoclonal antibody to the epidermal growth factor receptor, active for advanced colorectal cancer treatment in combination with chemotherapy. Cetuximab mainly acts by inhibiting epidermal growth factor receptor-mediated pathways in cancer cells; however, in the human host, its IgG1 backbone may offer additional antitumor activity that includes FcγRs-mediated antibody-dependent cell cytotoxicity, phagocytosis, cross priming, and tumor-specific T-cell-mediated immune response. These mechanisms are still under active investigation. At this purpose, we have performed an immunologic investigation in advanced colon cancer patients enrolled in an ongoing phase…

MaleCancer Researchmedicine.medical_treatmentCetuximabPharmacologyDeoxycytidineAldesleukinT-Lymphocyte SubsetsImmunology and AllergyCytotoxic T cellEpidermal growth factor receptorChemoimmunotherapybiologyCetuximabAntibodies MonoclonalMiddle AgedRecombinant ProteinsAdvanced Colorectal CancerErbB ReceptorsKiller Cells NaturalFemaleFluorouracilImmunotherapyAntibodyColorectal NeoplasmsImmune-modulating Effectmedicine.drugImmunologyAntineoplastic AgentsAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleImmunomodulationImmune systemCell Line TumormedicineHumansPharmacologyEpidermal growth factor receptorPolychemotherapybusiness.industryImmunotherapyDendritic CellsColorectal cancerGemcitabineCase-Control StudiesCancer cellbiology.proteinInterleukin-2CamptothecinbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Structural and functional characterization of a human IgG monoclonal antiphospholipid antibody

2009

Antiphospholipid antibodies (aPL) are likely involved in the pathogenesis of the antiphospholipid syndrome (APS). This study analyzes the structural and functional characteristics of a human monoclonal aPL (HL7G) from the IgG2 subtype with λ light chains generated from a patient with primary APS and recurrent cerebral microemboli. DNA encoding the variable region of heavy and light chains of the antibody was sequenced, analyzed, and compared to HL5B a previously described monoclonal aPL from the same patient. Both antibodies are derived from the same germline genes. HL7G had similar but more extensive somatic mutations in the CDR1 and 2 regions than HL5B, indicating that both antibodies are…

MaleCardiolipinsmedicine.drug_classImmunologySomatic hypermutationComplementarity determining regionMonoclonal antibodyImmunoglobulin light chainThromboplastinAntigenimmune system diseasesAntiphospholipid syndromemedicineHumansImmunology and AllergyneoplasmsCells CulturedMolecular StructurebiologyAntibodies MonoclonalT-Lymphocytes Helper-InducerHematologyMiddle AgedAntiphospholipid Syndromemedicine.diseaseComplementarity Determining RegionsMolecular biologybeta 2-Glycoprotein IImmunoglobulin GImmunologyMonoclonalAntibodies Antiphospholipidbiology.proteinSomatic Hypermutation ImmunoglobulinAntibodyImmunobiology
researchProduct

Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.

1999

Abstract Circulating plasma cells in 10 cases of reactive plasmacytosis had a shared phenotype with early plasma cell (CD19+CD38+ CD138+ CD40+CD45+ CD11a+ CD49e−CD56−). In most cases, a minor subpopulation of CD28+ plasma cells was also detected. Reactive plasma cells were highly proliferative, suggesting the presence of circulating progenitors (plasmablasts). After CD138+ plasma cell removal, highly proliferative CD138− plasmablasts differentiated into CD138+ plasma cells within a few days. This differentiation, which was associated with increased CD38 and decreased HLA-DR expression, was further confirmed by a large increase in intracellular Ig content (associated with Ig secretion) and w…

MaleCellular differentiationRemission SpontaneousApoptosisCD38Plasma cellBiochemistry0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesChildCells Cultured[INFO.INFO-BI] Computer Science [cs]/Bioinformatics [q-bio.QM]0303 health sciencesbiologyAntibodies MonoclonalCell DifferentiationHematologyMiddle Agedmedicine.anatomical_structureFemaleAntibodyMultiple MyelomaAdultPlasma CellsImmunologyLymphocytosisCD19ImmunophenotypingImmunoglobulin kappa-Chains03 medical and health sciencesImmunoglobulin lambda-ChainsAntigens CD[ INFO.INFO-BI ] Computer Science [cs]/Bioinformatics [q-bio.QM]medicineHumansProgenitor cellAgedRetrospective Studies030304 developmental biologyCD40Interleukin-6PlasmacytosisCell Biologymedicine.diseaseHematopoietic Stem CellsMolecular biologyReceptors Interleukin-6Immunologybiology.protein[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM]030215 immunology
researchProduct